Photocure ASA (PHCUF) 4.6000 $PHCUF Acne Vulgaris

New Post Public Reply Private Reply Replies (0) Message Board

Jun 15, 2016 at 3:09 AM

Photocure ASA (PHCUF) 4.6000 $PHCUF

Acne Vulgaris Pipeline Review 2015
M2 - Wed Jan 27, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcgrnr/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acne Vulgaris Overview - Therapeutics Development - Pipeline Products for Acne Vulgaris - Overview - Pipeline Products for Acne Vulgaris - Comparative Analysis - Acne Vulgaris - Therapeutics under Development by Companies - Acne Vulgaris - Therapeutics under Investigation by Universities/Institutes - Acne Vulgaris - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acne Vulgaris - Products under Development by Companies - Acne Vulgaris - Products under Investigation by Universities/Institutes - Acne Vulgaris - Companies Involved in Therapeutics Development - 3SBio Inc. - Advancell - Allergan Plc - Almirall, S.A. - Biomar Microbial Technologies - Braintree Laboratories, Inc. - Brickell Biotech, Inc. - Celtaxsys, Inc. - Cosmo Pharmaceuticals S.p.A - Delenex Therapeutics AG - Deltanoid Pharmaceuticals Inc. - DermaXon, LLC - Dermira Inc. - ELORAC, Inc. - Ensol Biosciences Inc. - Foamix Pharmaceuticals Ltd. - Galderma S.A. - GlaxoSmithKline Plc - Helix BioMedix, Inc. - Hovione FarmaCiencia SA - Lee's Pharmaceutical Holdings Limited - Maruho Co., Ltd. - Novabiotics Limited - Novan, Inc. - OrigImm e.U. - Paratek Pharmaceuticals, Inc. - Phosphagenics Limited - Photocure ASA - Promius Pharma, LLC - Provectus Biopharmaceuticals, Inc. - RestorGenex Corporation - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - SkyePharma Plc - Telesso Technologies Limited - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/xc...e_vulgaris
FOMX: 6.15 (-0.05), GSK: 40.05 (-0.78), PRTK: 16.89 (+0.35), AGN: 244.10 (+0.55), PVCT: 0.38 (+0.01), DERM: 29.28 (-0.59)

BioSyent Pharma Acquires Exclusive Rights For Cysview(R) In Canada
Marketwired - Wed Aug 19, 7:01AM CDT
BioSyent Inc. ("BioSyent"

(TSX VENTURE: RX) announced today that its subsidiary BioSyent Pharma Inc. has signed an agreement with Photocure ASA granting BioSyent the exclusive rights for Cysview(R) in Canada. Cysview(R) (hexaminolevulinate hydro-chloride) is an innovative technology that aids in the diagnosis and management of bladder cancer and was approved by Health Canada in January 2015. It has been successfully marketed in the USA, Europe, and the Nordic region, since 2006. Commercialization of Cysview(R) in Canada will commence this year. Under the terms of the agreement, Photocure will receive up to USD $1,000,000 in milestone payments for the rights to Cysview in Canada, which includes USD $650,000 upon signing of the agreement.
PHO: 23.16 (+0.07), RX.VN: 7.550 (unch)

Acne Vulgaris Pipeline Review 2015 - 40 Companies & 53 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mtb2tv/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advancell - Allergan, Inc. - AndroScience Corporation - Biomar Microbial Technologies - Braintree Laboratories, Inc. - Brickell Biotech, Inc. - Celtaxsys, Inc. - Cosmo Pharmaceuticals S.p.A - Cutanea Life Sciences - Delenex Therapeutics AG - Deltanoid Pharmaceuticals Inc. - Dermira Inc. - ELORAC, Inc. - Ensoltek Co., Ltd. - Foamix Pharmaceuticals Ltd. - Galderma S.A. - GlaxoSmithKline plc - Helix BioMedix, Inc. - Hovione FarmaCiencia SA - Kasiak Research Pvt. Ltd. - Lee's Pharmaceutical Holdings Limited - Maruho Co., Ltd. - Nabriva Therapeutics AG - Novabiotics Ltd - Novan, Inc. - OrigImm e.U. - Paratek Pharmaceuticals, Inc. - Phosphagenics Limited - Photocure ASA - Provectus Biopharmaceuticals, Inc. - QLT Inc. - RestorGenex Corporation - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Telesso Technologies Limited - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mt...e_vulgaris
QLTI: 1.43 (-0.02), FOMX: 6.15 (-0.05), GSK: 40.05 (-0.78), PRTK: 16.89 (+0.35), AGN: 244.10 (+0.55), PVCT: 0.38 (+0.01), DERM: 29.28 (-0.59), NBRV: 7.08 (+0.01)

Biophotonics - Global Strategic Business Report 2015: Medical (Therapeutics, Diagnostics, & Others), and Non-Medical
M2 - Wed Jul 15, 2:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d7g95g/biophotonics) has announced the addition of the "Biophotonics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Biophotonics in US$ Million by the following End-Use Sectors: Medical (Therapeutics, Diagnostics, & Others), and Non-Medical. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 85 companies including many key and niche players such as - AdvanDx, Inc. (US) - Affymetrix, Inc. (US) - Andor Technology plc (Ireland) - Becton, Dickinson and Company (US) - BioTek Instruments, Inc. (US) - BIOLASE, Inc. (US) - Carl Zeiss MicroImaging GmbH (Germany) - CEA-Leti (France) - Endra, Inc. (US) - Epi-Light Limited (Ireland) - FEI Company (US) - Glenbrook Technologies, Inc. (US) - Hamamatsu Photonics K.K. (Japan) - HORIBA, Ltd. (Japan) - Lumenis Ltd. (Israel) - Newport Corporation (US) - Ocean Optics, Inc. (US) - Olympus America, Inc. (US) - PerkinElmer, Inc. (US) - Photocure ASA (Norway) - PicoQuant GmbH (Germany) - Solta Medical, Inc. (US) - Zecotek Photonics, Inc. (Singapore) - Zenalux Biomedical, Inc. (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. MARKET TRENDS, ISSUES AND DRIVERS 3. AN INTRODUCTION TO BIOPHOTONICS 4. PRODUCT INNOVATIONS/INTRODUCTIONS 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT GLOBAL PLAYERS 7. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 85 (including Divisions/Subsidiaries 88) - The United States (45) - Canada (5) - Japan (4) - Europe (30) - - France (3) - - Germany (9) - - The United Kingdom (3) - - Spain (2) - - Rest of Europe (13) - Asia-Pacific (Excluding Japan) (2) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/d7...ophotonics
NEWP: 22.99 (-0.02), LMNS: 13.76 (+0.04), BIOL: 1.18 (unch), PKI: 53.25 (+0.15), AFFX: 14.01 (+0.02), FEIC: 106.99 (-0.34)

New Data Provide Evidence that Hexvix® Can Improve the Overall Survival in Bladder Cancer Patients
PR Newswire - Thu Jan 29, 3:12AM CST
In a retrospective study Hexvix fluorescence-guided bladder resection significantly improved overall survival and recurrence free survival compared to resection performed with standard white light
PHO: 23.16 (+0.07)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....